Path BioAnalytics, Inc. (PBA) is developing novel precision medicine tools by combining innovative epithelial cell culture technology with proprietary analytics.
Organoids are unique three-dimensional cell cultures in which polarized cells aggregate to form tiny spheres. Each organoid is a miniature model of the in vivo cellular architecture and is unique to the person who provided the cells to grow the organoid. PBA’s organoids utilize easily accessible cells and do not require induced pluripotency.
- Derived from patients who have the disease of interest,
- Replicate patient-specific characteristics,
- Grown from progenitor cells that differentiate into target cell types, and
- Exhibit multi-scale biological function and mimic the in vivo cellular architecture.
Keywords: organoid, spheroid, 3D cell culture, patient-derived disease model, primary cells, epithelial cells, in vitro, predictive modeling, respiratory, ACE2, COVID-19, SARS-CoV-2, nCoV
High throughput compound screening against SARS-CoV-2 in human airway epithelial organoids. Readouts include viral titers, viral gene copy number, differential gene expression and inflammatory markers, and others.
PBA collects human biological specimens from healthy individuals as well as those living with cystic fibrosis, pulmonary fibrosis, asthma, COPD, and other diseases from consenting donors under IRB-approved protocols from sites located in the United States. Specimens include human nasal epithelial cell samples collected via nasal brushing or nasal curettage, and saliva samples. For each specimen donor, clinical data are collected such as gender, age, race/ethnicity, smoking history, etc.
Keywords: human biospecimens, prospective human tissue collection, biological specimens, nasal, epithelial cells, healthy, disease, saliva samples, biorepository, biobank, donor-matched
PBA uses its proprietary organoids derived from primary human epithelial cells to conduct high throughput screening.
Keywords: drug development, drug discovery, therapeutic compound, screening, candidate, lead compound, organoids, spheroid, 3D cell culture, patient-derived, primary cells, epithelial cells, in vitro, predictive modeling, biotechnology, assay, personalized medicine
Path BioAnalytics has not received any reviews.
Path BioAnalytics has not received any endorsements.